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OBJECTIVES We sought to assess the ability of a new noninvasive method to quantify atherosclerosis
severity and to examine its power to predict cardiovascular events.
BACKGROUND Drug prevention of cardiovascular events is effective but costly, leading to a debate about who
should receive this treatment. Patient selection is often based on surrogate markers, but
quantification of atherosclerosis severity is desirable.
METHODS Atherosclerosis severity was quantified by determination of specific aortic wall elastance in
transthoracic echocardiography, applying the biomechanics of pulse wave propagation. After
validating the method in 52 patients by measuring aortic plaque burden in transesophageal
echo directly, another 336 patients were prospectively studied by monitoring atherosclerotic
events at one year and comparing the results with conventional risk stratification.
RESULTS Specific aortic elastance was well correlated with plaque burden (p  0.0001) and largely
independent of confounding variables. Specific aortic elastance predicted the primary end
point of “atherosclerotic death, myocardial infarction or stroke” at one year (p  0.0002).
Event rate at one year in the lowest specific elastance tertile was 1.8% (CI 0.0% to 4.3%), in
the middle tertile 5.4% (CI 1.1% to 9.7%) and in the highest tertile 12.7% (CI 6.3% to 19%).
Secondary end points supported these findings. Stepwise multivariate analysis identified
specific aortic elastance, prior atherosclerotic events and left ventricular ejection fraction as
independent risk predictors. Specific elastance was of incremental value to clinically identified
variables.
CONCLUSIONS Bedside measurement of specific aortic elastance allows assessment of atherosclerosis
severity. It predicts the risk for future atherosclerotic events beyond conventional risk
factors, promising better targeting of pharmacologic prevention and improved cost
effectiveness. (J Am Coll Cardiol 2002;39:702–9) © 2002 by the American College of
Cardiology
With cardiovascular diseases as the leading cause of death
in the Western world, prevention of atherosclerosis and
its complications is a major goal of healthcare. The
introduction of powerful lipid-lowering drugs has
brought unprecedented mortality reductions in secondary
(1) and primary prevention (2). However, in an era of cost
awareness and limited resources, this has also led to a
debate about who should be treated. Individuals are often
selected using surrogate markers of atherosclerosis, such
as prior cardiovascular events, number of risk factors and
lipids levels. This allows identification of the subjects at
highest risk, but for the large population at moderate risk,
better strategies are needed.
We hypothesized that quantification of atherosclerosis
severity might improve risk stratification compared with
that provided by conventional risk factor assessment (Fig.
1). To quantify atherosclerosis severity noninvasively, we
developed a novel echocardiographic bedside method,
which determines aortic elastic properties based on the
biomechanics of pulse wave-vessel wall interaction. The aim
of the study was: 1) to validate this method by direct
visualization of plaque burden in transesophageal echocar-
diography (TEE), and 2) to determine the value of the
method for risk stratification versus use of conventional risk
factors, prospectively in a large patient cohort.
METHODS
Rationale. Atherosclerosis leads to thickening and stiffen-
ing of the arterial wall through fibrosis, calcification, plaque
formation and smooth muscle cell proliferation. In biome-
chanical terms, this implies changes of material properties of
the artery (increase in Young’s elastic modulus E), and an
increased wall thickness (h). The Moens-Korteweg equa-
From the *Medical Intensive Care Unit and Division of Cardiology, University
Hospital, Basel, Switzerland; and †Cardiac Unit, Department of Medicine, Massa-
chusetts General Hospital, Boston, Massachusetts. Presented in part (validation part)
at the Young Investigator’s Award Competition of the American College of
Cardiology 1999.
Manuscript received June 12, 2001; revised manuscript received October 26, 2001,
accepted November 13, 2001.
Journal of the American College of Cardiology Vol. 39, No. 4, 2002
© 2002 by the American College of Cardiology ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(01)01780-6
tion (3), describing wave propagation in elastic tubes filled
with inviscid fluid
c2 
Eh
fD
with c: wave propagation velocity
E: Young’s modulus (circumferential)
h: wall thickness
f: fluid density
D: vessel diameter
can be rearranged to obtain
Eh  c2fD
In other words, the product of E and h, the key
parameters influenced by atherosclerosis, can be determined
by measuring wave front velocity, fluid density and vessel
diameter (although E and h are difficult to measure indi-
vidually). The product Eh is termed “specific elastance”
throughout this article. Blood density can be considered
constant (4). Wave front velocity and vessel diameter are
measurable by ultrasound, as shown in Figure 2.
Study design. Two independent consecutive patient co-
horts were prospectively studied. Measurements were per-
formed during diagnostic transesophageal (TEE; validation
part) and transthoracic (TTE; risk stratification part) echo-
cardiography, and results were compared to aortic plaque
burden, conventional risk factors and cardiovascular events.
The validation part included 52 consecutive patients re-
ferred for TEE. The risk stratification part included 336
consecutive patients referred for TTE. There were no
exclusion criteria.
Determination of specific elastance. Echo/Doppler mea-
surements (Fig. 2) were performed with a Sonos 5500
echocardiograph (Hewlett Packard, Andover, Massachu-
setts), the S4 transthoracic probe and the 5.0/3.7 MHz
transesophageal probe, with readers blinded for plaque
burden and outcome, respectively.
Pulsed-wave Doppler recordings were acquired from the
left ventricular outflow tract and the left common femoral
artery in the groin. Wave front arrival at each location was
defined by extrapolation of the ascending Doppler flow
profile to the baseline, using the electrocardiographic R
wave as time reference. Mean aortic diameter was deter-
mined by TTE from measurements 1 cm above the sino-
tubular junction (parasternal window, feasibility 99%), at
the origin of the left subclavian artery (suprasternal window,
feasibility 98%) and at the diaphragm (substernal window,
feasibility 98%). Wave front velocity was calculated as wave
front delay (outflow tract to femoral artery) divided by aortic
length. The latter was determined as follows: aortic length 
0.41 m/m body length, a formula derived from catheter-
based measurements during coronary angiography in 22
patients (mean 0.41 m/m, SD 0.024 m/m). Wave front
velocity, mean aortic radius determined by TTE and blood
density (4) (1,060 kg/m3) were substituted to calculate
specific aortic elastance. Using SI units (meter, seconds)
scaled by 103, result units are kiloNewton/meter (kN/m).
Repeatability (one observer, repeated data acquisition), in-
traobserver variability (repeated measurement in the same
images) and interobserver variability were determined in
groups of 20 patients.
Aortic plaque burden. By TEE, short axis slices were
acquired in the ascending aorta at the pulmonary artery
crossing, at the origin of the left subclavian artery and in the
Abbreviations and Acronyms
CI  confidence interval
HDL  high density lipoproteins
SD  standard deviation
TEE  transesophageal echocardiography
TTE  transthoracic echocardiography
Figure 1. Rationale of study.
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descending aorta just distal to the arch, at its lowest visible
portion, and halfway between. Maximum plaque thickness
and extent (circumferential arc) were determined in each
slice. Average plaque thickness and extent were calculated as
mean of the five measurements. Plaque burden in milliliters
was calculated as average plaque thickness times average
plaque arc length times aortic length.
Aortic compliance and distensibility (conventional meth-
ods). By TEE, the aortic diameter change with the cardiac
cycle (mean of five locations) was measured, and pulse
pressure was determined by brachial sphygmomanometry.
Aortic compliance was calculated as area change divided by
pulse pressure (method A) (5), and aortic distensibility was
calculated as fractional area change divided by pulse pressure
(6). Alternatively, aortic compliance was determined from
wave front velocity and blood pressure (method B) (7).
Risk factors, prior events, revascularizations. Cardio-
vascular risk factors, prior history of ischemic events and
revascularization procedures were assessed by patient inter-
views, patient records and blood lipid determinations. A
positive family history was defined as myocardial infarction,
revascularization or cerebrovascular events before the age of
65 years. Hypercholesterolemia was defined as untreated
total cholesterol 6.5 mmol/l or total cholesterol 5.2 to 6.5
mmol/l, with total cholesterol to HDL ratio 5.
Outcome. Follow-up at one year was done by telephone
interview of patients and referring physicians, with hospital
chart review in case of events. Atherosclerotic events were
defined as stroke, myocardial infarction and interventional
or surgical revascularization of coronary, cranial, abdominal
or peripheral arteries, counting only one event per patient
for composite outcome variables. Nonatherosclerotic death
was defined as cancer death, death in a patient with another
life-threatening nonatherosclerotic disease and violent
death. Atherosclerotic death was defined as death occurring
with acute coronary syndromes, stroke or unexpected death
in patients with documented coronary artery or cerebrovas-
cular disease but without life-threatening nonatherosclerotic
disease. The predefined primary end point was a composite
of atherosclerotic death, myocardial infarction or stroke at
one year. Secondary end points were overall and atheroscle-
rotic death, nonfatal infarction, stroke, revascularization
procedures and combinations thereof.
For calculation of relative risk and to determine the
presence of an incremental relation of atherosclerosis sever-
ity and event risk, tertiles of specific aortic elastance and
different levels of other risk predictors were also analyzed.
To yield an age-corrected measure of specific aortic elas-
tance, analyses were also performed after dividing the cohort
into three age strata and classifying patients in each stratum
into three tertiles of specific aortic elastance.
Statistics. Statistics were done using StatView Software
5.01 (Abacus Inc., Berkeley, California). Data are described
as mean, 95% confidence interval (CI), standard deviation
(SD), median and interquartile width according to data
distribution and use. Because of skew distribution, specific
elastance and plaque burden were log transformed for
analysis. Fisher’s exact test, t tests and regression analysis
were used. Linear regression was used for the validation part
(univariate comparison of plaque burden with parameters of
arterial mechanics, univariate and multivariate analysis of
potential confounding factors for specific elastance).
In the risk stratification part, event risk was calculated for
tertiles of different predictors of cardiovascular events. Lo-
gistic regression was used with the primary end point as
dependent variable. In an exploratory analysis, a multivariate
logistic model, initially including those factors that were
significant in univariate analysis, was used, with stepwise
elimination of variables not significant in the likelihood
ratio test. To examine the incremental value of specific
elastance, the likelihood ratio test was also applied to a
model including only clinically identifiable variables with
and without specific elastance.
RESULTS
Validation part. Fifty-two patients were studied. Mean age
was 57 (SD: 17; range: 27 to 83) years. Thirty (58%) were
men. By TTE, mean aortic diameter was 2.4 cm (SD:
Figure 2. Method for determination of specific aortic elastance by trans-
thoracic echocardiography: Wave front propagation time from the left
ventricular outflow tract to the common femoral artery is measured using
pulsed wave Doppler. The wave front is defined as the extrapolation of the
first segment of the Doppler flow profile to the baseline. Average aortic
diameter is determined from measurements in the ascending aorta, the
aortic arch and the abdominal aorta. All measurements are made using a
conventional echocardiograph.
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0.3 cm) and mean wavefront delay was 90 ms (SD: 24 ms).
By TEE, median plaque burden was 16 ml (interquartile
width: 33 ml; range: 0.3 to 244 ml), mean aortic diameter
was 2.4 cm (SD: 0.4 cm) and mean aortic diameter change
was 1.3 mm (SD: 0.5 mm).
Median specific aortic elastance was 1.6 kN/m (inter-
quartile width: 1.4; range: 0.5 to 6.7 kN/m). Repeatability
was 9.1%, intraobserver variability was 4.9% and interob-
server variability was 9.0% of the measured range.
An excellent correlation of noninvasively measured spe-
cific elastance by TTE with plaque burden visible in TEE
was found (Fig. 3). Uni- and multi-variate analysis of the
potential confounding factors of age, blood pressure and
aortic diameter documented the robustness of specific elas-
tance as a measure of plaque burden (Table 1). While
associated with a stiffer vessel in univariate analysis, these
factors did not significantly contribute to specific aortic
elastance independent from plaque burden in multivariate
analysis. The merits of the new method for determination of
plaque burden was then compared to wave front velocity,
aortic compliance, aortic distensibility and pulse pressure
(Table 2); specific elastance proved to be the best parameter
of atherosclerosis severity.
Risk stratification part. In this cohort, 336 patients with a
mean age of 63 (SD: 15; range: 11 to 92) years were
included. Of these, 206 (61%) were men. Mean serum
cholesterol was 5.3 (SD: 1.2) mmol/l, mean HDL choles-
terol was 1.3 (SD: 0.41) mmol/l and mean LDL cholesterol
Figure 3. Validation of the new bedside method for quantification of the severity of atherosclerosis by determination of elastic properties of the aortic wall.
Specific elastance of the aorta shows an excellent correlation with plaque extent (left upper panel), with plaque thickness (left lower panel) and thus with
overall atherosclerotic plaque burden (right panel), determined by direct visualization in transesophageal echo.
Table 1. Robustness of the Correlation of Plaque Burden and Specific Aortic Elastance Against Potential Confounding Variables
Determinants of Specific Aortic Elastance
Univariate Analysis Multivariate Model
Adjusted R2
Regression
Coefficient (CI) p Value Adjusted R2
Regression
Coefficient (CI) p Value
Aortic plaque burden 0.75 0.28 (0.25–0.33)  0.0001 0.28 (0.18–0.38)  0.0001
Potential confounding variables
Age 0.58 0.011 (0.009–0.014)  0.0001 0.002 (0.001–0.006) 0.2
Systolic blood pressure 0.24 0.006 (0.003–0.009) 0.0003 0 (0.002–0.002) 0.93
Mean aortic diameter 0.13 0.31 (0.09–0.51) 0.006 0.09 (0.25–0.7) 0.25
Entire model 0.76  0.0001
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was 3.3 (SD: 1.0) mmol/l. Two hundred and three patients
fulfilled the criteria for hypercholesterolemia. There were 87
smokers, 61 patients with a positive family history of
cardiovascular events and 49 diabetic patients. Mean left
ventricular ejection fraction was 54 (SD: 14)% and was
below 50% in 22% of patients. There was a history of prior
myocardial infarction in 62, of stroke in 32 and of arterial
revascularization procedures in 44 patients.
Median specific aortic elastance was 1.8 kN/m (inter-
quartile width: 1.5; range: 0.2 to 23 kN/m). Stratification in
three tertiles showed mean specific elastance values of 1.1,
1.8 and 4.5 kN/m, respectively.
In univariate analysis, an increase in specific elastance was
associated with hypercholesterolemia (p  0.018), hyper-
tension (p  0.0006), diabetes (p  0.0011) and increasing
age (p  0.0001), but not significantly with gender (p 
0.76), positive family history of cardiovascular events (p 
0.37), smoking (p  0.10) or left ventricular ejection
fraction (p  0.26). The relation between age, the number
of risk factors and specific aortic elastance is shown in
Figure 4, documenting that in a cohort with a moderate
number of risk factors (Fig. 4A), specific aortic elastance
values span a wide range (Fig. 4B). Specific elastance does
not simply reflect age (Fig. 4E) or the number of risk factors
(Fig. 4F).
A history of prior cardiovascular events was also associ-
ated with higher specific aortic elastance (p  0.001); this
was true for myocardial infarction (p  0.05) and stroke
(p  0.01).
Table 2. Comparison of Different Parameters of Arterial
Mechanics a Measures of Aortic Plaque Burden
Method R2
Regression Coefficient
(CI) p Value
Specific elastance 0.76 2.7 (2.2–3.1)  0.0001
Wave front velocity 0.59 0.25 (0.19–0.31)  0.0001
Distensibility 0.48 65 (86–44)  0.0001
Compliance (method A*) 0.23 21 (9.5–34) 0.001
Compliance (method B*) 0.69 1.04 (1.24–0.84)  0.0001
Pulse pressure 0.31 0.25 (0.13–0.36)  0.0001
Simple regression analysis. *See methods section.
Figure 4. The relation of age, cardiovascular risk factors and specific aortic elastance. In a cohort with a moderate number of risk factors (A) and with the
age distribution given in C that reflects the referral pattern for cardiologic examination, specific aortic elastance spans a wide range (B). Specific elastance
does not simply reflect age (E) or the number of risk factors (D).
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Outcome. Follow-up at one year could be ascertained in
99.7% of patients, with one patient lost to follow-up because
of emigration to another continent. At follow-up, 21
patients had died. Death was due to nonatherosclerotic
disease in nine patients: malignant tumors in seven, dilated
cardiomyopathy with nonstenosed coronary arteries in one
and pulmonary embolism in one. There were no violent
deaths. Death was attributable to atherosclerosis in 12
patients. Nonfatal infarction occurred in five patients, stroke
in seven. Revascularization had been performed by coronary
angioplasty in 8, by aortocoronary bypass operation in 10
and by carotid interventions in 3 patients. The composite
primary end point was reached in 22 patients. Hospitaliza-
tion for any cause had taken place in 116 patients.
Specific aortic elastance was strongly associated with
subsequent occurrence of the primary end point (atheroscle-
rotic death, myocardial infarction or stroke at one year; p 
0.0002). Median specific aortic elastance in patients with a
primary end point was 2.5 kN/m (interquartile width: 1.6),
but in the other patients it was only 1.7 kN/m (interquartile
width: 1.5). The event rate for the primary end point in the
lowest tertile (1.43 kN/m) of specific elastance was 1.8%
(CI 0.0% to 4.3%), in the middle tertile 5.4% (CI 1.1% to
9.7%), but in the highest tertile of specific elastance (2.33
kN/m) 12.7% (CI 6.3% to 19%). Relative risk for various
levels of several risk factors is given in Figure 5.
Specific aortic elastance also predicted the secondary end
point “atherosclerotic death” (p  0.002), while the number
of nonfatal strokes (n  7) and nonfatal myocardial infarc-
tions (n  5) was insufficient for analysis. The combined
secondary end points “all death, myocardial infarction,
stroke” (p  0.02) and “nonfatal myocardial infarction or
stroke” (p  0.03) were likewise predicted by aortic specific
elastance. No significantly increased revascularization rate in
patients with higher specific aortic elastance was observed
(p  0.8).
Age-corrected specific elastance likewise predicted the
primary end point (p  0.007) and the secondary combined
end point “nonfatal infarction or stroke” (p  0.03). There
was no association of specific aortic elastance with nonath-
erosclerotic death or with hospitalization for any cause.
Other univariate predictors of the primary end point were
age (p  0.001), prior atherosclerotic events (p  0.02), left
ventricular ejection fraction (p  0.01) and positive family
history (p  0.04). Significance for the primary end point
was not reached by “number of cardiovascular risk factors”
(p 0.11) or by the Framingham risk model (8) (p 0.34);
the latter predicted the composite secondary end point “all
death, infarction, stroke or revascularization” (p  0.03).
Nonsignificant trends for an increased risk for the primary
end point were also seen for increased plasma cholesterol,
low HDL cholesterol, smoking, diabetes and left ventricular
hypertrophy (as determined by echocardiography). The
relative risk for the primary end point of several levels of
multiple risk factors is shown in Figure 5.
In stepwise logistic regression, the following independent
Figure 5. Relative risk for the primary end point (death attributable to
atherosclerosis, nonfatal myocardial infarction or stroke) of different levels
of multiple risk factors. An increase in specific elastance leads to a marked
increase in event risk for each tertile of specific elastance. CAD coronary
artery disease; LV  left ventricular; MI  myocardial infarction.
707JACC Vol. 39, No. 4, 2002 Hunziker et al.
February 20, 2002:702–9 Quantifying Atherosclerosis Severity
predictors of the primary end point emerged: specific
elastance (p  0.009), prior events (p  0.03) and, of
borderline significance, left ventricular ejection fraction
(p  0.053), while age, gender and number of risk factors
were not independently predictive. In the model including
only clinically identified variables and specific elastance, the
latter was incrementally significant (p  0.05).
DISCUSSION
In this study, bedside quantification of atherosclerosis se-
verity by determination of specific aortic elastance was
shown to strongly reflect atheromatous plaque burden in the
aorta measured by direct visualization. This parameter
strongly and independently predicted cardiovascular event
risk in a prospective cohort of individuals referred for
cardiologic evaluation for any reason.
Pathologists have long observed that widespread athero-
sclerotic vascular changes usually precede clinical manifes-
tations of atherosclerosis by many years. The results of this
study document the feasibility of quantifying the severity of
atherosclerosis noninvasively at the bedside as part of an
examination that is often already being performed, using
technology currently available to the cardiologist. The
findings further confirm the working hypothesis that non-
invasive quantification of atherosclerosis severity might be as
promising for risk prediction as are classical “risk factors.”
The echo method used for quantification, which is based
on the biomechanics of pulse wave propagation, was robust
to possible confounding factors in the range studied and
compared favorably with previously described parameters of
pulse wave-aortic wall interaction.
Biomechanical considerations. Atherosclerosis is anatom-
ically defined as thickening and stiffening of the arterial wall
through fibrosis, calcification and plaque formation with
smooth muscle cell proliferation of intimal and/or medial
layers (9). A method to quantify atherosclerosis severity
would, therefore, preferably be sensitive to both, an in-
creased wall thickness (h), and changes in elastic tissue
properties (Young’s modulus E). Vessel stiffening resulting
from these pathologic alterations induces changes in pulse
wave propagation. Bifurcations and wave reflections make
complete mathematical modeling of pulse wave propagation
difficult, but when only the wave front is considered, which
is unaltered by reflections, the Moens-Korteweg equation
describing wave propagation in elastic tubes can be ex-
ploited. It predicts that the product of Young’s modulus and
wall thickness (Eh), here termed specific elastance, is
determined by wave front velocity, vessel diameter and
blood density. More complicated, nonlinear equations have
been thoroughly studied in vitro (10) but may be too
complex and not needed clinically, as the pressure-
dependent change in elastic properties is only moderate at
physiologic blood pressures (11,12). Aortic elastic properties
have been determined from human autopsy material (13),
and average specific elastance calculated from those data was
1.4 kN/m and 2.2 kN/m for thoracic and abdominal aorta,
with a 10-fold increase with atherosclerosis, thus showing
an excellent agreement with our findings.
Prior studies. These findings extend prior approaches
studying pulse wave-vessel wall interactions: aortic compli-
ance (5,7,14,15), distensibility (6), pulse pressure (16) and
pulse wave velocity (17). Compared to these, specific elas-
tance as measured in the present study appears better
justified as a measure of atherosclerosis from a biomechani-
cal standpoint and was better correlated with atherosclerosis
severity in the current study. By focusing on incomplete
biomechanical models or on indirect parameters of mechan-
ical wall properties, these other methods might be sensitive
to confounders: e.g., pulse wave velocity (18) does not
control for vessel diameter; distensibility and compliance
measurements suffer from the inaccessibility of the aorta for
pressure measurement. In addition, studies validating other
methods by determination of arteriosclerotic burden are
lacking, and prospective data about the value for risk
stratification in individuals are limited (19,20).
Study limitations. It might be argued that atherosclerosis
severity in the aorta does not equal organ-specific vascular
changes (e.g., coronary atherosclerosis, due to uneven dis-
tribution of this process in different vascular territories).
Although this is correct when organ-specific invasive diag-
nostic procedures such as coronary angiography are consid-
ered, less organ-specific screening methods such as the one
described might even be advantageous for institution of
preventive measures with known benefit in multiple arterial
territories (like lipid lowering). The inclusion criterion
(referral to an echocardiogram for any reason) represents
patient selection, allowing application of our results only to
specific settings with similar patient populations. To con-
firm applicability and value of the method to the population
at large, population-based studies will be needed. Large
outcome studies are also needed for exhaustive multivariate
characterization of additional factors relevant for outcome
and for definitive head-to-head comparison of different
methods, for which the current study was underpowered.
Certain simplifications of biomechanics were necessary to
keep the method practical, but they apply to all patients
similarly (blood as noncompressible fluid with constant
density, determination of average aortic diameter by a
limited number of measurements, aortic length as a function
of body height). Limited echo windows may put an obstacle
to measurement of aortic diameters; in our case, with
experienced echocardiographers using modern equipment
with harmonic imaging, this was only a problem in 1% to
2% of patients; at least two aortic diameters were available in
all patients. Aortic plaques may have a complex three-
dimensional morphology, limiting the accuracy of plaque
volume determinations, but because these complex plaques
usually occur only with very severe atherosclerosis, we do
not believe that this problem led to frank misclassification of
our patients.
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Clinical implications. Improved noninvasive assessment
of global cardiovascular risk is valuable in many situations.
In the first line, it may be used in a patient population
similar to the one reported, i.e., in patients referred for
noninvasive cardiovascular examination, to improve cardio-
vascular risk estimation and for better selection of high-risk
individuals for additional exams and for institution of
preventive measures.
Furthermore, individualized risk assessment may also be
important for asymptomatic individuals with multiple risk
factors or occupational risks, such as pilots. In these,
recommendations for lifestyle changes may be better justi-
fied and possibly more convincing if atherosclerosis is
documented objectively. Lastly, this method might improve
patient selection for “primary” prevention of atherosclerosis
(e.g., by pharmacologic lipid lowering) to those with objec-
tively documented but clinically silent atherosclerosis, elim-
inating all patients with risk factors but no echocardio-
graphic evidence of atherosclerosis, with a favorable impact
on cost effectiveness in cardiovascular prevention. Noninva-
sive quantification of atherosclerosis severity will probably
enhance, but not replace, conventional risk factor assess-
ment, as these analyses offer complementary information.
We conclude that bedside quantification of atherosclero-
sis severity is feasible by echocardiographic determination of
specific aortic elastance and is strongly associated with the
risk of future complications of atherosclerosis beyond con-
ventional risk factors. It therefore promises better cardio-
vascular risk stratification and improved targeting of “pri-
mary” and secondary prevention.
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